The Commissioner of the Food and Drug Administration (FDA) stated that he is ready to expedite production of the “Covid-19” vaccine as soon as possible, according to the “Financial Times” newspaper, quoting him, in an interview published on Sunday.
Dr. Stephen Hahn, Commissioner of the US Food and Drug Administration, said that his administration is ready to license the vaccine before the completion of the third phase of clinical trials, as long as officials are convinced that the benefits outweigh the risks, the newspaper reported.
Han insisted that the move would not be due to pressure from the Trump administration to produce a rapid vaccine, and said that emergency clearance may be appropriate before the third phase of clinical trials is completed if the benefits outweigh the risks.
This news comes a week after the US Food and Drug Administration granted an emergency permit to use convalescent plasma in treating patients with “Covid-19” in hospitals, despite concerns of some health officials that data from clinical trials is too weak to support the widespread application of this treatment so far. .
This follows President Trump’s accusation to the Food and Drug Administration, without any evidence, of trying to harm him politically by slowing down approval of vaccines and treatments for the new Coronavirus.
Last Saturday, Trump accused members of the so-called “deep state” in the Food and Drug Administration of working to slow down tests for “Covid-19” vaccines and delay them until after the US presidential elections scheduled for November 3.
A day later, the Food and Drug Administration granted an “emergency use permit” to treat the Coronavirus, which uses blood plasma from recovered patients.
“Our license for emergency use is not the same as full approval,” Hahn told the Financial Times, adding that his decisions were not made due to political pressure.
He continued, “This is a decision related to science, medicine and data. It will not be a political decision.”
And he continued, saying that the safest way to make the vaccine available for use before the end of Phase III trials, which involve thousands of patients and can take years, would be through issuing an emergency permit for use by certain groups rather than blanket approval.